BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A repression

Division of Hematology-Oncology, Department of Pediatrics, Childrens Hospital Los Angeles, CA 90027, USA.
Cancer Research (Impact Factor: 9.28). 09/2008; 68(16):6507-15. DOI: 10.1158/0008-5472.CAN-07-6152
Source: PubMed

ABSTRACT Deregulation of the polycomb group gene BMI-1 is implicated in the pathogenesis of many human cancers. In this study, we have investigated if the Ewing sarcoma family of tumors (ESFT) expresses BMI-1 and whether it functions as an oncogene in this highly aggressive group of bone and soft tissue tumors. Our data show that BMI-1 is highly expressed by ESFT cells and that, although it does not significantly affect proliferation or survival, BMI-1 actively promotes anchorage-independent growth in vitro and tumorigenicity in vivo. Moreover, we find that BMI-1 promotes the tumorigenicity of both p16 wild-type and p16-null cell lines, demonstrating that the mechanism of BMI-1 oncogenic function in ESFT is, at least in part, independent of CDKN2A repression. Expression profiling studies of ESFT cells following BMI-1 knockdown reveal that BMI-1 regulates the expression of hundreds of downstream target genes including, in particular, genes involved in both differentiation and development as well as cell-cell and cell-matrix adhesion. Gain and loss of function assays confirm that BMI-1 represses the expression of the adhesion-associated basement membrane protein nidogen 1. In addition, although BMI-1 promotes ESFT adhesion, nidogen 1 inhibits cellular adhesion in vitro. Together, these data support a pivotal role for BMI-1 ESFT pathogenesis and suggest that its oncogenic function in these tumors is in part mediated through modulation of adhesion pathways.

Download full-text


Available from: Elizabeth R Lawlor, Jul 29, 2015
  • Source
    • "Transcription factor Bmi-1(B lymphoma mouse moloney leukemia virus insertion region-1) is critical for the cell-cycle progression, and it can act as a positive regulator for DNA damage response and mitochondrial function [49]. It is also essential for promoting selfrenewal of several types of normal and cancer stem cells [50] [51] [52] [53]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are a class of endogenous, non-coding, 18-24 nucleotide length single-strand RNAs that could modulate gene expression at post-transcriptional level. Previous studies have shown that miR-128 enriched in the brain plays an important role in the development of nervous system and the maintenance of normal physical functions. Aberrant expression of miR-128 has been detected in many types of human tumors and its validated target genes are involved in cancer-related biological processes such as cell proliferation, differentiation and apoptosis. In this review, we will summarize the roles of miR-128 and its target genes in tumorigenesis and metastasis.
    Experimental Cell Research 08/2013; 319(20). DOI:10.1016/j.yexcr.2013.07.031 · 3.37 Impact Factor
  • Source
    • "fragment into pFB Hygro (adapted from pFB neo from Agilent, Cheshire, UK). Oligos targeting NDN (Supplementary Table 3) or a non-silencing control oligo (Douglas et al, 2008) were cloned into pRetroSuper-puro (Tomlinson et al, 2007). Constructs were transfected into PhoenixA (ATCC) using Mirus TransIT-293 (Cambridge Bioscience, Cambridge, UK). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Necdin (NDN) expression is downregulated in telomerase-immortalised normal human urothelial cells. Telomerase-immortalised normal human urothelial cells have no detected genetic alterations. Accordingly, many of the genes whose expression is altered following immortalisation are those for which epigenetic silencing is reported. Methods: NDN expression was examined in normal tissues and tumour cell lines by quantitative real-time PCR and immunoblotting. Immunohistochemistry was performed on urothelial carcinoma (UC). Urothelial carcinoma and UC cell lines were subject to HumanMethylation27 BeadChip Array-based methylation analyses. Mutation screening was performed. The functional significance of NDN expression was investigated using retroviral-mediated downregulation or overexpression. Results: NDN protein was widely expressed in normal tissues. Loss of expression was observed in 38 out of 44 (86%) of UC cell lines and 19 out of 25 (76%) of non-UC cell lines. Loss of NDN protein was found in the majority of primary UC. Oncomine analysis demonstrated downregulation of expression in multiple tumour types. In UC, tumour-specific hypermethylation of NDN and key CpG sites where hypermethylation correlated with reduced expression were identified. Six novel mutations, including some of predicted functional significance, were identified in colorectal and ovarian cancer cell lines. Functional studies showed that NDN could suppress colony formation at low cell density and affect anchorage-independent growth and anoikis in vitro. Conclusion: NDN is a novel tumour suppressor candidate that is downregulated and hypermethylated or mutated in cancer.
    British Journal of Cancer 04/2013; 108(6):1368-77. DOI:10.1038/bjc.2013.104 · 4.82 Impact Factor
  • Source
    • "We employed an in vitro adhesion assay (Douglas et al., 2008) and determined that cells expressing Sox2 shRNAs do not show altered adherence to substratum (Supplementary Figure S3). These results indicate that depletion of Sox2 markedly reduces the in vitro-transformed phenotype of osteosarcoma cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumors are thought to be sustained by a reservoir of self-renewing cells, termed tumor-initiating cells or cancer stem cells. Osteosarcomas are high-grade sarcomas derived from osteoblast progenitor cells and are the most common pediatric bone malignancy. In this report we show that the stem cell transcription factor Sox2 is highly expressed in human and murine osteosarcoma (mOS) cell lines as well as in the tumor samples. Osteosarcoma cells have increased ability to grow in suspension as osteospheres, that are greatly enriched in expression of Sox2 and the stem cell marker, Sca-1. Depletion of Sox2 by short-hairpin RNAs in independent mOS-derived cells drastically reduces their transformed properties in vitro and their ability to form tumors. Sox2-depleted osteosarcoma cells can no longer form osteospheres and differentiate into mature osteoblasts. Concomitantly, they exhibit decreased Sca-1 expression and upregulation of the Wnt signaling pathway. Thus, despite other mutations, these cells maintain a requirement for Sox2 for tumorigenicity. Our data indicate that Sox2 is required for osteosarcoma cell self renewal, and that Sox2 antagonizes the pro-differentiation Wnt pathway that can in turn reduce Sox2 expression. These studies define Sox2 as a survival factor and a novel biomarker of self renewal in osteosarcomas, and support a tumor suppressive role for the Wnt pathway in tumors of mesenchymal origin. Our findings could provide the basis for novel therapeutic strategies based on inhibiting Sox2 or enhancing Wnt signaling for the treatment of osteosarcomas.
    Oncogene 09/2011; 31(18):2270-82. DOI:10.1038/onc.2011.405 · 8.56 Impact Factor
Show more